As many of the oncogenic mutations that drive constitutive NF-κB activity in ABC-DLBCL occur upstream of the IKK complex, functional disruption of this complex represents an attractive universal strategy for the treatment of ABC-DLBCL that arises from different oncogenic mutations [14]. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.